HSAQ vs. INFU, NSPR, CTCX, TMDIF, GBS, RVP, PETV, BTCY, INVO, and TTOO
Should you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include InfuSystem (INFU), InspireMD (NSPR), Carmell (CTCX), Titan Medical (TMDIF), GBS (GBS), Retractable Technologies (RVP), PetVivo (PETV), Biotricity (BTCY), INVO Bioscience (INVO), and T2 Biosystems (TTOO). These companies are all part of the "surgical & medical instruments" industry.
Health Sciences Acquisitions Co. 2 vs. Its Competitors
InfuSystem (NYSE:INFU) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.
In the previous week, InfuSystem had 9 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 9 mentions for InfuSystem and 0 mentions for Health Sciences Acquisitions Co. 2. InfuSystem's average media sentiment score of 0.80 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media.
InfuSystem has a net margin of 1.12% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Health Sciences Acquisitions Co. 2's return on equity.
InfuSystem has higher revenue and earnings than Health Sciences Acquisitions Co. 2.
InfuSystem presently has a consensus target price of $12.50, suggesting a potential upside of 107.99%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Health Sciences Acquisitions Co. 2.
71.1% of InfuSystem shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 10.2% of InfuSystem shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
InfuSystem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.
Summary
InfuSystem beats Health Sciences Acquisitions Co. 2 on 11 of the 13 factors compared between the two stocks.
Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Sciences Acquisitions Co. 2 Competitors List
Related Companies and Tools
This page (NASDAQ:HSAQ) was last updated on 7/25/2025 by MarketBeat.com Staff
